title: Impact of TGF-β1 Gene Polymorphism (rs1800469) on Treatment Response to Pegylated Interferon/Ribavirin in Iranian Patients with Hepatitis C.
abstract: BACKGROUND
  Hepatitis C virus as a major cause of chronic liver disease affects more than 170 million people worldwide. Recent studies have claimed that single nucleotide polymorphisms (SNPs) for the transforming growth factor-β1 (TGF-β1) gene were strongly associated with the antiviral treatment response. Thus, the present study aimed at the determination of distribution of the rs1800469 (C/T) polymorphism among Iranian with chronic hepatitis C.
  
  
  METHODS
  A total of 165 blood samples including 68 SVR positive and 21 non-responder samples from individuals suffering chronic hepatitis C and also 76 healthy individual controls were analyzed in this cross-sectional study. DNA was isolated from the samples using a DNA extraction standard kit. Then the frequency of the polymorphism was analyzed using PCR-RFLP method. Eventually, the products of interest were detected on 2.5% agarose gel electrophoresis.
  
  
  RESULTS
  The distribution of the C/T polymorphism between healthy individuals and patients were obtained as TT: 22.4%, TC: 46%, CC: 31.6%, and TT: 19.1%, TC: 48.3%, CC: 32.6%, respectively. Furthermore, the CC genotype was identified in 20 patients of whom 68 achieved SVR, while the CT heterozygous was found in 43 patients and SVR was achieved in 38. Finally, the TT was detected in 17 patients, and 7 patients did not achieve SVR.
  
  
  CONCLUSIONS
  We observed a significant difference of C allele frequency with SVR as compared to the T allele among patients (p = 0.064). On the other hand, there is no correlation between the polymorphism and susceptibility to HCV infection. However, further studies with more samples seem to be necessary.
authors.forename: Mona Sadat
authors.initials: MS
authors.lastname: Larijani
authors.forename: Leila Naghizadeh
authors.initials: LN
authors.lastname: Rad
authors.forename: Mehri
authors.initials: M
authors.lastname: Nikbin
authors.forename: Narges
authors.initials: N
authors.lastname: Bahiraei
authors.forename: Foozieh
authors.initials: F
authors.lastname: Javadi
authors.forename: Mahtab
authors.initials: M
authors.lastname: Daneshvar
authors.forename: Mohammad Reza
authors.initials: MR
authors.lastname: Aghasadeghi
authors.forename: Pooneh
authors.initials: P
authors.lastname: Rahimi
authors.forename: Seyed Davar
authors.initials: SD
authors.lastname: Siadat
authors.forename: Rezvan
authors.initials: R
authors.lastname: Zabihollahi
authors.forename: Seyed Mehdi
authors.initials: SM
authors.lastname: Sadat
mesh_terms: D000328:Adult; D003430:Cross-Sectional Studies; D004359:Drug Therapy, Combination; D005260:Female; D005838:Genotype; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000235:genetics*; D006801:Humans; D007372:Interferons / Q000008:administration & dosage; D008297:Male; D020641:Polymorphism, Single Nucleotide; D012254:Ribavirin / Q000008:administration & dosage*; D053773:Transforming Growth Factor beta1 / Q000235:genetics*
chemical_list: D053773:Transforming Growth Factor beta1; D012254:Ribavirin; D007372:Interferons